Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study.
Acid Anhydride Hydrolases
/ genetics
Carcinoma, Mucoepidermoid
/ diagnosis
Cyclin-Dependent Kinase Inhibitor p27
/ genetics
Humans
Mitogen-Activated Protein Kinase 1
/ genetics
Mitogen-Activated Protein Kinase 3
/ genetics
Neoplasm Proteins
/ genetics
Prognosis
Retrospective Studies
Salivary Gland Neoplasms
/ diagnosis
Salivary Glands
FHIT
Salivary gland carcinoma
p27
pERK1/ERK2
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
26
07
2018
accepted:
11
01
2019
pubmed:
24
1
2019
medline:
18
12
2019
entrez:
24
1
2019
Statut:
ppublish
Résumé
The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas. Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined. Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival. Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer. The results may help to stratify patient-specific therapies according to individual tumor characteristics.
Identifiants
pubmed: 30673867
doi: 10.1007/s00784-019-02809-z
pii: 10.1007/s00784-019-02809-z
doi:
Substances chimiques
CDKN1B protein, human
0
Neoplasm Proteins
0
fragile histidine triad protein
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
MAPK1 protein, human
EC 2.7.11.24
MAPK3 protein, human
EC 2.7.11.24
Mitogen-Activated Protein Kinase 1
EC 2.7.11.24
Mitogen-Activated Protein Kinase 3
EC 2.7.11.24
Acid Anhydride Hydrolases
EC 3.6.-
Types de publication
Journal Article
Langues
eng
Pagination
3801-3809Références
J Cancer. 2016 Jan 10;7(3):314-23
pubmed: 26918045
Am J Pathol. 2003 Sep;163(3):957-67
pubmed: 12937136
Curr Treat Options Oncol. 2017 Jul;18(7):43
pubmed: 28639231
Mod Pathol. 2002 Dec;15(12):1366-73
pubmed: 12481019
Br J Cancer. 2005 Jun 20;92(12):2206-15
pubmed: 15928662
Oral Dis. 2002 Sep;8(5):229-40
pubmed: 12363107
J Clin Oncol. 2009 Dec 10;27(35):5924-30
pubmed: 19884556
Oral Oncol. 2012 Sep;48(9):822-30
pubmed: 22445095
Oral Oncol. 2010 Mar;46(3):195-9
pubmed: 20060354
J Biol Chem. 2001 Nov 2;276(44):40888-95
pubmed: 11527971
Biochem Biophys Res Commun. 2010 Apr 30;395(2):219-24
pubmed: 20361940
Oral Oncol. 2006 Nov;42(10):1005-10
pubmed: 16757206
Br J Cancer. 2010 Aug 10;103(4):510-6
pubmed: 20664595
Cancer Res. 2001 Jun 15;61(12):4827-36
pubmed: 11406559
Surg Oncol. 2006 Aug;15(2):97-106
pubmed: 17123889
Surg Oncol. 2006 Dec;15(4):223-33
pubmed: 17382535
Hum Pathol. 2012 Jun;43(6):921-31
pubmed: 22154363
Br J Cancer. 2012 Feb 14;106(4):719-26
pubmed: 22240798
Cancer Res. 2014 Jan 15;74(2):412-9
pubmed: 24408923
Virchows Arch. 2013 Jan;462(1):65-72
pubmed: 23242174
Cancer Immunol Immunother. 2009 Mar;58(3):469-73
pubmed: 18663445
Mod Pathol. 2001 Oct;14(10):1008-14
pubmed: 11598171
Hum Pathol. 2008 Jan;39(1):126-36
pubmed: 17949785
Lancet Oncol. 2002 Dec;3(12):748-54
pubmed: 12473516
ScientificWorldJournal. 2014 Mar 16;2014:179698
pubmed: 24757411
Int J Cancer. 2005 Apr 20;114(4):509-12
pubmed: 15578717
Cancer. 2014 Nov 15;120(22):3446-56
pubmed: 24948110
Histopathology. 2008 Nov;53(5):567-77
pubmed: 18983466
Oncogene. 2006 May 11;25(20):2860-72
pubmed: 16407838
Nat Rev Cancer. 2008 Apr;8(4):253-67
pubmed: 18354415